Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE‐LY trial analysis

[1]  E. Hylek,et al.  Incidence of severe renal dysfunction among individuals taking warfarin and implications for non–vitamin K oral anticoagulants , 2017, American heart journal.

[2]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[3]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[4]  L. Wallentin,et al.  Renal Function in Atrial Fibrillation: A Multifaceted Dilemma , 2016, Circulation.

[5]  A. Parkhomenko,et al.  Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. , 2016, JAMA cardiology.

[6]  E. Antman,et al.  Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial , 2015, Circulation.

[7]  G. Breithardt,et al.  On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF , 2015, Circulation.

[8]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  S. Yusuf,et al.  Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. , 2015, Journal of the American College of Cardiology.

[10]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[11]  S. Yusuf,et al.  Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.

[12]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[13]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[14]  G. Lip,et al.  Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). , 2013, The American journal of cardiology.

[15]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[16]  B. Pitt,et al.  Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study , 2012, Circulation.

[17]  C. Rowley.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[18]  D. Singer,et al.  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. , 2011, European heart journal.

[19]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[20]  P. McCullough,et al.  Validity of Estimated Glomerular Filtration Rates for Assessment of Baseline and Serial Renal Function in Patients With Atherosclerotic Renal Artery Stenosis: Implications for Clinical Trials of Renal Revascularization , 2011, Circulation. Cardiovascular interventions.

[21]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[22]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[23]  S. Yusuf,et al.  Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.

[24]  D. Singer,et al.  Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.

[25]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[26]  D. Singer,et al.  Factor V Leiden and Risk of Ischemic Stroke in Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2003, Journal of Thrombosis and Thrombolysis.